

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6





FIG. 7



pA2HG1apgpt

A circular map of the pA2HuKapgpt plasmid. The plasmid is 3.0 kb in size. Key features include: pBR (plasmid backbone region), Ecogpt (neomycin resistance gene), HCK (HindIII cloning site), and several restriction enzyme sites: BamHI, BglIII, XbaI, HindIII, and EcoRI. The map also shows the locations of the L, A2, and Vk genes.



FIG. 9a




FIG. 9b




FIG. 10a




FIG. 10b




FIG. 11





FIG. 12



# FIG. 13

1	Val	Arg	Ser	Ser	Arg	Thr	Pro	Ser	Asp	Lys	Pro	Val	Ala	His	Val	Val	Ala	Asn	Pro
21	Gln	Ala	Glu	Gly	Gln	Leu	Gln	Trp	Leu	Asn	Arg	Ala	Asn	Ala	Leu	Leu	Ala	Asn	Gly
41	Val	Glu	Leu	Arg	Asp	Asn	Gln	Leu	Val	Val	Pro	Ser	Glu	Gly	Leu	Tyr	Leu	Ile	Tyr
61	Gln	Val	Leu	Phe	Lys	Gly	Gln	Gly	Cys	Pro	Ser	Thr	His	Val	Leu	Leu	Thr	His	Thr
81	Ser	Arg	Ile	Ala	Val	Ser	Tyr	Gln	Thr	Lys	Val	Asn	Leu	Leu	Ser	Ala	Ile	Lys	Ser
101	Cys	Gln	Arg	Glu	Thr	Pro	Glu	Gly	Ala	Glu	Ala	Lys	Pro	Trp	Tyr	Glu	Pro	Ile	Tyr
121	Gly	Gly	Val	Phe	Gln	Leu	Glu	Lys	Gly	Asp	Arg	Leu	Ser	Ala	Glu	Ile	Asn	Arg	Pro
141	Tyr	Leu	Asp	Phe	Ala	Glu	Ser	Gly	Gln	Val	Tyr	Phe	Gly	Ile	Ile	Ala	Leu		

FIG. 14a




FIG. 14b





FIG. 15

1 Val Arg Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro  
10  
21 Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu Leu Ala Asn Gly  
30  
41 Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser Glu Gly Leu Tyr Leu Ile Tyr Ser  
50  
61 Gln Val Leu Phe Lys Gly Gln Gly Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile  
70  
81 Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro  
90  
101 Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys Pro Trp Tyr Glu Pro Ile Tyr Leu  
110  
121 Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp  
130  
141 Tyr Leu Asp Phe Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu  
150

[illegible]

# Figure 16



Docket No.: 0975.1005-012  
Title: Anti-TNF Antibodies and Peptides...  
Inventors: Junming Le, *et al.*

Figure 17A

CA2 LIGHT CHAIN VARIABLE REGION SEQUENCE

GACATCTTGCTCAGTCAGTCTCCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCAGT  
AspIleLeuLeuThrGlnSerProAlaIleLeuSerValSerProGlyGluArgValSer

TTCTCCTGCACGGCCAGTCAGTTCGTTGGCTCAAGCATCCACTGGTATCAGCAAAGAACA  
PheSerCysArgAlaSerGlnPheValGlySerSerIleHisTrpTyrGlnGlnArgThr

AATCGTTCTCCAAGGCTTCTCATAAAGTATGCTTCTGAGTCTATGTCTGGGATCCCTTCC  
AsnGlySerProArgLeuLeuIleLysTyrAlaSerGluSerMetSerGlyIleProSer

AGGTTTAGTGGCAGTGGATCAGGGACAGATTTTACTGTTAGCATCAACACTCTGCAGTGT  
ArgPheSerGlySerGlySerGlyThrAspPheThrLeuSerIleAsnThrValGluSer

GAAGATATTGCAGATTATTACTGTCAAGAAAGTCATAGCTGCCCATTCACGTTCCGCTCG  
GluAspIleAlaAspTyrTyrCysGlnGlnSerHisSerTrpProPheThrPheGlySer

CGGACAAATTTGCAAGTAAAA  
GlyThrAsnLeuGluVallys

0975.1005-012



Parameter	Unit	Value	Standard Error	t-value	p-value
$\alpha_1$		0.0000	0.0000	0.0000	0.0000
$\alpha_2$		0.0000	0.0000	0.0000	0.0000
$\alpha_3$		0.0000	0.0000	0.0000	0.0000
$\alpha_4$		0.0000	0.0000	0.0000	0.0000
$\alpha_5$		0.0000	0.0000	0.0000	0.0000
$\alpha_6$		0.0000	0.0000	0.0000	0.0000
$\alpha_7$		0.0000	0.0000	0.0000	0.0000
$\alpha_8$		0.0000	0.0000	0.0000	0.0000
$\alpha_9$		0.0000	0.0000	0.0000	0.0000
$\alpha_{10}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{11}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{12}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{13}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{14}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{15}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{16}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{17}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{18}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{19}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{20}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{21}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{22}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{23}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{24}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{25}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{26}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{27}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{28}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{29}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{30}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{31}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{32}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{33}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{34}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{35}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{36}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{37}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{38}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{39}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{40}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{41}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{42}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{43}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{44}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{45}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{46}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{47}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{48}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{49}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{50}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{51}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{52}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{53}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{54}$		0.0000	0.0000	0.0000	0.0000
$\alpha_{55}$		0.0000	0.0000</		

Figure 17B

## anti-TNF Trial

### EMS




FIG-18

## anti-TNF Trial

## Pain





FIG. 19

## anti-TNF Trial

### Ritchie Articular Index



## anti-TNF Trial

### Swollen Joints




FIG 21

## anti-TNF Trial

### CRP




FIG. 22

## anti-TNF Trial

### ESR




FIG 23

## anti-TNF Trial

### Index of Disease Activity




FIG 24



# SWOLLEN JOINT COUNTS IN PATIENTS WITH RA FOLLOWING CA2 ADMINISTRATION




FIGURE 25

# EFFECT OF cA2 ADMINISTRATION ON CRP LEVELS IN PATIENTS WITH RA




FIGURE 2.6



27  
A27  
B

FIGURE 27A-B




FIGURE 28




FIGURE 29

2025-04-22 10:00




FIGURE 30




FIGURE 31




FIGURE 32



A)




FIGURE 33 A

B)




FIGURE 33 B

C)




FIGURE 33 C






FIGURE 34



FIGURE

35 A



FIGURE

35 B